Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the moving parts behind a global derivatives powerhouse can feel overwhelming. CME Group鈥檚 annual reports stretch past 200 pages, and its Form 4 insider notices drop without warning鈥攐ften right before rate-sensitive futures rallies. If you have ever asked, 鈥淲here can I find CME Group鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I decode clearinghouse risk in the 10-K?鈥�, you are not alone.
Stock Titan solves this complexity. Our AI-powered summaries turn dense disclosures into plain-English briefs鈥攕o understanding CME Group SEC documents with AI becomes routine. Need CME Group insider trading Form 4 transactions? We stream CME Group Form 4 insider transactions real-time, flagging executive stock transactions the moment they reach EDGAR. Looking for revenue per contract or margin requirements? The platform highlights them automatically within the CME Group annual report 10-K simplified, while our dashboard links every footnote to the relevant accounting rule.
You will find every filing type鈥�10-K, 10-Q, 8-K, DEF 14A, S-8鈥攊ndexed and searchable. Click the 10-Q tab for a concise CME Group earnings report filing analysis; open any 8-K for CME Group 8-K material events explained in seconds. The proxy section answers, 鈥淲hat鈥檚 inside the CME Group proxy statement executive compensation?鈥� by extracting pay ratio, incentive targets, and peer comparisons. AG真人官方-time alerts keep you ahead when material events hit or when directors buy shares. Whether you monitor fee trends, hedge fund positioning, or just want CME Group SEC filings explained simply, Stock Titan provides the clarity professionals need鈥攁ll in one place.
CME Group director Bryan T. Durkin reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Durkin now beneficially owns 47,207 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Code A)
- Ownership Type: Direct
- Role: Director
- Total Value of Transaction: $145,251.96
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye
CME Group director Charles P. Carey reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 Class A Common Stock shares at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Carey's beneficial ownership consists of:
- 5,779 shares held indirectly through trust
- 185 shares held indirectly through firm
- 0.375 shares held indirectly through partnership
The Form 4 filing indicates this was a planned acquisition under the director compensation program rather than an open market transaction. No derivative securities were involved in this transaction.
CME Group director William W. Hobert reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share through the CME Group Director Stock Plan.
Following the transaction, Hobert's holdings include:
- 86,598 shares held directly
- 40,000 shares held indirectly through his firm
The transaction was executed pursuant to the company's Director Stock Plan, as amended and restated. The Form 4 was filed on behalf of Hobert by Jenelle Chalmers on June 26, 2025, within the required reporting timeframe.
CME Group director Martin J. Gepsman reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Gepsman now beneficially owns a total of 25,299 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
- Transaction Type: Stock Award (Code A)
- Ownership Form: Direct
- Filing Status: Individual filing
- Role: Director (non-employee)
This insider transaction represents routine director compensation and aligns with standard corporate governance practices for board member equity compensation.
CME Group Inc. (CME) filed a Form 4 disclosing that Director Howard J. Siegel acquired 879 shares of Class A common stock on 06/25/2025 at $273.03 per share under the company鈥檚 Director Stock Plan. Following the purchase, Siegel holds 47,791 shares directly and 21,873 shares indirectly through a trust. No derivative transactions or share dispositions were reported.
Form 4 filing 鈥� CME Group Inc. (CME)
Director Dennis Suskind received 532 Class A common shares on 25 Jun 2025 under the CME Group Director Stock Plan. The grant price recorded for reporting purposes is $273.03 per share, implying a total market value of roughly $145 k. Following the award, Suskind鈥檚 direct beneficial ownership rose to 3,447 shares, an increase of about 18%. No open-market purchases, sales, or derivative transactions were reported, and there is no indication of a 10b5-1 trading plan. The transaction represents routine director compensation and does not materially affect CME鈥檚 share count or capital structure.
Form 4 overview: On 06/25/2025 CME Group Inc. (CME) director Kathryn Benesh reported an acquisition of Class A common stock.
The filing shows a single non-derivative transaction coded 鈥淎(1),鈥� indicating a grant under the company鈥檚 amended and restated Director Stock Plan. Benesh received 532 shares at a reference value of $273.03 per share. Following the grant, her aggregate beneficial ownership increased to 2,106.948 shares, held directly.
No derivative securities were listed and the Form 4 contains no sales, option exercises, or 10b5-1 plan activity. The grant is routine annual director compensation rather than an open-market purchase, so cash outlay by the director is not implied. While the transaction modestly aligns director and shareholder interests, it represents an immaterial fraction of CME鈥檚 ~360 million Class A shares outstanding and therefore is unlikely to affect valuation or trading dynamics.
Insider transaction overview: On 06/25/2025 director Robert J. Tierney Jr. filed a Form 4 reporting the acquisition of 532 shares of CME Group Inc. (CME) Class A common stock.
Key details
- Transaction type: Code A 鈥� acquisition under the CME Group Director Stock Plan.
- Per-share price reported: $273.03.
- Total shares acquired: 532.
- Beneficial ownership after the transaction: 13,700 direct shares.
The filing indicates the shares were granted pursuant to the company鈥檚 director compensation plan rather than an open-market purchase. No derivative securities were reported. The director remains classified as an 鈥淥fficer/Director鈥� insider and the filing was signed on 06/26/2025 by attorney-in-fact Jenelle Chalmers.
While the size of the acquisition is modest relative to CME鈥檚 average daily volume, any increase in board-level ownership can be viewed as enhancing alignment between the director and shareholders.
CME Group Inc. (CME) 鈥� Form 4 insider activity dated 06/25/2025
Director William R. Shepard reported three separate Class A common-stock acquisitions:
- 879 shares were granted under the CME Group Director Stock Plan (transaction code A) with a reference price of $273.03. Shares are held indirectly in a trust. Post-grant indirect holdings: 257,939.99 shares.
- Through a dividend-reinvestment plan, the trust purchased 256.097 shares in the open market (code P) at an average price of $270.53. Indirect holdings after the trade: 258,196.087 shares.
- Shepard鈥檚 direct account purchased 11.29 shares at $270.53, raising direct ownership to 2,454.76 shares.
No derivative securities were reported. The filing was signed on 06/26/2025.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
What does CME Group do?
How does CME Group generate revenue?
What is CME Globex?
What is CME Clearing?
What are some key products offered by CME Group?
How does CME Group support sustainability?
What is CME Group's global reach?
Who are CME Group's customers?
What role does CME Group play in financial markets?
How does CME Group differentiate itself from competitors?
